Navigation Links
NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
Date:2/12/2008

LAWRENCE, Mass., Feb. 12 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its financial results for the fourth quarter and year ended December 31, 2007.

Revenues for the fourth quarter of 2007 were $29.9 million, compared to $7.4 million in the fourth quarter of 2006 and $11.6 million in the third quarter of 2007. Revenues for the fourth quarter of 2007 include revenues from the acquisition of Medisystems Corporation beginning as of October 1, 2007. Revenues in the chronic home dialysis market were $9.3 million for the fourth quarter of 2007, compared to $4.6 million in the fourth quarter of 2006 and $8.3 million in the third quarter of 2007. Revenues in the critical care market for the fourth quarter of 2007 were $4.9 million, compared to $2.7 million in the fourth quarter of 2006 and $3.3 million in the third quarter of 2007. Revenues in the in-center market, from the Company's Medisystems business, were $15.7 million in the fourth quarter of 2007.

Full year 2007 revenues were $60.0 million, including revenues from the Medisystems acquisition in the fourth quarter, a 188% increase compared to $20.8 million for the full year 2006. Full year 2007 revenues in the chronic home dialysis market totaled $29.8 million, a 134% increase compared to $12.7 million for the full year 2006. For the full year 2007, critical care revenues were $14.4 million, a 78% increase compared to $8.1 million for the full year 2006.

At the end of 2007, NxStage was working with 334 dialysis centers to provide home hemodialysis therapy to 2,223 end-stage renal disease (ESRD) patients using the Company's System One(TM) portable dialysis machine. This compares to 174 centers and 1,022 patients at the end of the fourth quarter of 2006 and 306 centers and 1,957 patients at the end of the third quarter of 2007. NxStage also continued to expand use of the PureFlow SL(TM) to a broader customer base and at the end of the fourth quarter 2007, PureFlow penetration reached 70% of all System One machines in the chronic home dialysis market. Expanding penetration of PureFlow among existing and new customers is an important element of NxStage's ongoing focus to improve margins.

NxStage reported a net loss of $17.4 million, or ($0.47) per share, for the fourth quarter of 2007 compared with a net loss of $10.4 million, or ($0.37) per share, for the fourth quarter of 2006 and $16.1 million, or ($0.54) per share for the third quarter of 2007, reflecting improved gross margins offset by increased spending in sales and marketing in support of the ongoing launch of the System One and increased distribution expenses in the chronic home hemodialysis market. Fourth quarter 2007 net loss includes $3.2 million in charges primarily related to the acquisition of Medisystems that are not expected to recur.

For the full year 2007, the Company's net loss was $58.4 million, or ($1.86) per share, compared to a net loss of $39.6 million, or ($1.60) per share, in 2006, reflecting improved gross margins offset by increased spending in operating expenses as the Company continues to build its infrastructure to support the business.

Cash, cash equivalents and short term investments as of December 31, 2007 were $34.3 million, compared to $61.8 million at the end of 2006.

"2007 was a transformational year for NxStage. We completed a major, strategic acquisition that dramatically increased the Company's scale and capabilities. We are now in three dialysis markets: home, critical care and in-center," said Jeffrey H. Burbank, President & CEO of NxStage Medical. "In our existing business, we formed key supply and distribution agreements and grew our home hemodialysis revenues by 134%. We hope to build on this momentum and continue to lead the development of the home hemodialysis market in 2008."

Recent Highlights

-- In January 2008, the Company announced that it signed a five-year

agreement with DaVita Inc. to continue to supply DaVita's dialysis

centers with MasterGuard and ButtonHole safety needle sets. Safety

needles are essential products used to access patients' blood during

the vast majority of chronic dialysis therapy treatments. MasterGuard

is the leading product in this market in the United States, and became

part of NxStage's product portfolio through the Company's acquisition

of Medisystems.

-- In November 2007, the Company announced that it entered into a $50

million credit and security agreement from a group of lenders led by

Merrill Lynch Capital, for a term of 42 months. The credit facility

consists of a $30.0 million term loan and a $20.0 million revolving

credit facility. It provides NxStage with additional financial

flexibility to support the growing needs of the Company's commercial

operations.

-- In October 2007, NxStage completed its acquisition of Medisystems

Corporation and certain affiliated entities for 6.5 million shares of

NxStage common stock. The acquisition provides NxStage with increased

commercial, operational and financial scale, positioning the Company to

maintain its leadership in the developing home hemodialysis market, and

gaining the Company a new leadership position in the United States in-

center dialysis market.

2008 Guidance

For the first quarter 2008, the Company expects revenue to be in the range of $29 million to $31 million. The Company expects a net loss in the range of $14 million to $15 million or ($0.38) to ($0.41) per share, including estimated non-cash stock-based stock compensation charges of $1.4 million to $1.5 million. The Company expects to add 300 to 375 additional net patients and 20 to 30 new centers offering therapy with the NxStage System One during the first quarter.

For the full year 2008, NxStage expects revenue to be in the range of $130 million to $140 million. The Company expects a net loss in the range of $52 million to $56 million or ($1.41) to ($1.52) per share for the full year 2008, including estimated non-cash stock-based stock compensation charges of $6.0 million to 7.0 million and amortization of acquisition intangibles of $3.0 million. The Company expects to end the year with 3,700 to 4,100 patients at approximately 420 to 450 centers offering therapy with the NxStage System One.

Conference Call

NxStage will host a conference call at 9:00 a.m. Eastern Time on February 12, 2008 to discuss its fourth quarter and year end 2007 financial results. To listen to the conference call, please dial (888) 713-4214 for domestic callers and (617) 213-4866 for international callers. The passcode is 20821233. A replay of the conference call will be available two hours after the start of the call through February 26, 2008 by dialing 888-286-8010 (domestic) and 617- 801-6888 (international), passcode 30075901. An online archive of the conference call will also be available by accessing the Investor Information section of the Company's website at http://www.nxstage.com.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for home and/or daily hemodialysis products, the anticipated market acceptance and demand for NxStage's products, including those products recently acquired through the Medisystems acquisition, anticipated increases in the availability of, and market and patient awareness regarding, home hemodialysis, anticipated benefits of the Medisystems acquisition, anticipated reductions in cost of goods sold, anticipated margin improvements, anticipated patient and center numbers, expected PureFlow SL adoption and expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the Company's historical chronic patient drop and retention rates, changes in the regulatory environment, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2006, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and the Definitive Proxy Statement filed on September 12, 2007.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

NxStage Medical, Inc.

Consolidated Statements of Operations

(amounts in thousands, except per share data)

Three-months ended Twelve-months ended

December 31, December 31,

2007 2006 2007 2006

Revenues $29,934 $7,353 $59,964 $20,812

Cost of revenues 29,377 8,640 65,967 26,121

Gross profit (deficit) 557 (1,287) (6,003) (5,309)

Operating expenses:

Selling and marketing 6,354 3,742 21,589 14,356

Research and development 2,014 1,690 6,335 6,431

Distribution 4,237 2,257 13,111 7,093

General and administrative 5,206 2,211 13,046 8,704

Total operating expenses 17,811 9,900 54,081 36,584

Loss from operations (17,254) (11,187) (60,084) (41,893)

Other income (expense):

Interest income 506 962 2,855 3,236

Interest expense (646) (186) (1,167) (973)

(140) 776 1,688 2,263

Net loss $(17,394) $(10,411) $(58,396) $(39,630)

Net loss per share - basic and

diluted $(0.47) $(0.37) $(1.86) $(1.60)

Weighted average shares

outstanding, basic and diluted 36,678 27,779 31,426 24,817

NxStage Medical, Inc.

Consolidated Balance Sheets

(amounts in thousands, except per share data)

December 31, December 31,

2007 2006

ASSETS

Current assets:

Cash and cash equivalents $33,245 $49,959

Short-term investments 1,100 11,843

Accounts receivable, net 7,990 4,302

Due from Affiliate 435 -

Inventory 29,965 10,419

Prepaid expenses and other current assets 2,455 1,014

Total current assets 75,190 77,537

Property and equipment, net 12,146 3,026

Field equipment, net 30,885 20,616

Deferred cost of revenues 14,850 140

Intangibles, net 33,801 -

Goodwill 41,457 -

Other assets 2,057 406

Total assets $210,386 $101,725

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $21,887 $5,917

Accrued expenses 9,874 4,104

Due to affiliates 2,774 -

Current portion of long-term debt - 2,800

Total current liabilities 34,535 12,821

Deferred revenue 19,530 229

Long-term debt 25,000 4,617

Other long term obligations 1,604 649

Total liabilities 80,669 18,316

Commitments and contingencies - -

Stockholders' equity:

Common stock: par value $0.001,

100,000,000 shares authorized:

36,771,893 and 27,806,543 shares

issued and outstanding as of December 31,

2007 and December 31, 2006, respectively 37 28

Additional paid-in capital 311,172 206,848

Accumulated deficit (182,036) (123,640)

Accumulated other comprehensive income 544 173

Total stockholders' equity 129,717 83,409

Total liabilities and stockholders'

equity $210,386 $101,725

NxStage Medical, Inc.

Revenue by Market

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Chronic care market $9,337 $4,607 $29,835 $12,732

Critical care market 4,869 2,746 14,401 8,080

In-center market 15,728 - 15,728 -

Total revenues $29,934 $7,353 $59,964 $20,812

Business Metrics

December 31, September 30, December 31,

2007 2007 2006

Chronic patients on therapy 2223 1957 1022

Home dialysis centers with

System One 334 306 174

Investor Relations Contact

Stephanie Marks for NxStage

1-888-698-6472

ir@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NxStage Medical to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 7, 2008
2. NxStage(R) Medical to Report Fourth Quarter & Full Year 2007 Financial Results on Tuesday, February 12th
3. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
4. NxStage Medical Reports Third Quarter 2007 Results
5. NxStage Medical Completes Acquisition of Medisystems
6. Aircraft Medical Files Counter Action Against Verathon
7. NHS Choices Launches Medical News Guide to What Lies Behind the Headlines
8. Symmetry Medical to Provide Fourth Quarter 2007 General Business Update on February 14, 2008
9. Grubb & Ellis Healthcare REIT Acquires Medical Portfolio 1
10. Harnessing Human Energy for Medical Good
11. Pennsylvania Corrections Department to Extend Medical Contract, Save $55 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: